Johnson & Johnson and Legend Biotech report that 50% of patients treated with Carvykti for multiple myeloma survived five years post-treatment. This data underscores the potential long-term benefits of this therapy in a challenging disease area.
Ten patients out of 20 who received Johnson & Johnson and Legend Biotech’s Carvykti remained alive at five years of follow up.
Original title: “J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma”